CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Prone decubitusWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)


Name (Synonyms) Correlation
drug185 Anti-SARS-CoV2 Serology Wiki 0.71
drug1978 Questionnaire Wiki 0.21

Correlated MeSH Terms (4)


Name (Synonyms) Correlation
D013577 Syndrome NIH 0.11
D055371 Acute Lung Injury NIH 0.10
D012127 Respiratory Distress Syndrome, Newborn NIH 0.10
D012128 Respiratory Distress Syndrome, Adult NIH 0.09

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 Evaluation of Prone Position in Conscious Patients on Nasal High-flow Oxygen Therapy for COVID-19 Disease Induced Acute Respiratory Distress Syndrome

Acute Respiratory Distress Syndrome (ARDS) induces high mortality, particularly in the context of COVID-19 disease. Preliminary data from patients with ARDS related to COVID-19 disease appear to show significant effectiveness of prone positioning in intubated patients in terms of oxygenation as well as nasal high flow therapy before intubation. It should be noted that in Jiangsu province, secondarily affected, nasal high flow combined with the prone position was successfully integrated into care protocols. The investigators hypothesize that the combined application of nasal high flow and prone positioning can significantly improve the outcome of patients suffering from COVID-19 pneumonia by reducing the need for tracheal intubation and associated therapeutics such as sedation and paralysis, resulting in both individual and collective benefits in terms of use of scarce critical care resources. Investigators hypothesize that the combined application of nasal high-flow and prone positioning can significantly improve the outcome of patients suffering from COVID-19 pneumonia by reducing the need for intubation and associated therapeutics such as sedation and paralysis, resulting in both individual and collective benefits in terms of use of scarce critical care resources.

NCT04358939 Acute Respiratory Distress Syndrome COVID-19 Other: Prone decubitus
MeSH:Respiratory Distress Syndrome, Newborn Respiratory Distress Syndrome, Adult Acute Lung Injury Syndrome

Primary Outcomes

Description: Therapeutic failure is defined by death or intubation or use of non-invasive ventilation at two pressure levels.

Measure: Therapeutic failure within 14 days of randomization

Time: From randomization to day 14

Secondary Outcomes

Measure: Evolution of oxygenation (PaO2/FiO2 ratio or SpO2/FiO2 surrogate) over the 14 days following randomization

Time: From randomization to day 14

Measure: Evolution of the SpO2/FiO2 ratio during the first prone session

Time: From randomization to day 1

Description: ROX index is the ratio of pulse oximetry (SpO2)/fraction of inspired oxygen (FiO2) to respiratory rate.

Measure: Evolution of the ROX index during the first prone session

Time: From randomization to day 1

Description: Score reaches from 1 to 7, 7 indicates worse outcome

Measure: Evolution of the World Health Organization disease severity score of COVID

Time: From randomization to day 28

Description: Comfort evaluted by the patient through a visual analogical scale

Measure: Patient comfort before, during and after the first prone position session

Time: From randomization to day 1

Measure: Occurrence of skin lesions on the anterior surface of the body

Time: From randomization to day 28

Description: Invasive devices include : central and peripheric vascular catheters, tracheal tube, urinary catheter, chest tubes.

Measure: Displacement of invasive devices during reversals

Time: From randomization to day 28

Measure: Days of nasal High-Flow therapy use

Time: From randomization to day 28

Measure: Days spent in the intensive care unit and in the hospital

Time: From randomization to day 28

Measure: Mortality in the intensive care unit and in the hospital

Time: From randomization to day 28


No related HPO nodes (Using clinical trials)